Laura Giordano

89133, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Systemic Mastocytosis: Molecular Pathophysiology, WHO Diagnostic Framework, and KIT-Directed Targeted Therapies.

Systemic Mastocytosis: Molecular Pathophysiology, WHO Diagnostic Framework, and KIT-Directed Targeted Therapies.

Journal: Cancers

Published: June 16, 2026

Quality of Life in CAR-T Cell Therapy.

Quality of Life in CAR-T Cell Therapy.

Journal: Hematology reports

Published: April 24, 2026

Stem Cell Mobilization and Autologous Transplantation Outcomes After First-Line R-DA-EPOCH in High-Risk DLBCL and HGBCL: A Single-Center Retrospective Study.

Stem Cell Mobilization and Autologous Transplantation Outcomes After First-Line R-DA-EPOCH in High-Risk DLBCL and HGBCL: A Single-Center Retrospective Study.

Journal: Cancers

Published: April 12, 2026

Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care.

Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care.

Journal: Cancers

Published: January 20, 2026

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.

Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.

Journal: Journal of neuro-oncology

Published: January 08, 2026

Reduced relapse rate and improved GVHD/relapse free survival (GRFS) with pharmacokinetics-guided busulfan conditioning regimen for allogeneic stem cell transplantation in adult patients with myeloid hematologic malignancies.

Reduced relapse rate and improved GVHD/relapse free survival (GRFS) with pharmacokinetics-guided busulfan conditioning regimen for allogeneic stem cell transplantation in adult patients with myeloid hematologic malignancies.

Journal: Bone marrow transplantation

Published: December 19, 2025

Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Pretreatment tumor infiltrating lymphocytes and outcome in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Journal: Scientific reports

Published: November 07, 2025

Real-World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort.

Real-World Experience of Efficacy and Tolerability of Continuous Infusion Ifosfamide for Advanced Soft Tissue and Bone Sarcoma Patients: A Single Centre Retrospective Cohort.

Journal: Cancer medicine

Published: September 18, 2025

Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.

Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.

Journal: British journal of haematology

Published: September 04, 2025

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Journal: The oncologist

Published: June 16, 2025

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Journal: The oncologist

Published: June 16, 2025

Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis.

Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis.

Journal: British journal of haematology

Published: May 06, 2025

Showing 1-12 of 100

Last Updated: 09/26/2026